NEW YORK (GenomeWeb News) - Invitrogen’s share price jumped 10 percent today after the firm released third-quarter results that showed a double-digit increase in revenues and a swing from a loss to a profit.
 
The firm reported after the close of the market yesterday that its third-quarter revenues had spiked up 11 percent to $315 million and that last year’s losses had been turned to a $31 million profit.
 
The stock was up $8.34 at $91.41 in late afternoon trading today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.